Home/Pipeline/Alzheimer's Immunotherapy

Alzheimer's Immunotherapy

Alzheimer's Disease

ResearchActive

Key Facts

Indication

Alzheimer's Disease

Phase

Research

Status

Active

Company

POP Biotechnologies

About POP Biotechnologies

POP Biotechnologies leverages its proprietary porphyrin-phospholipid (PoP) nanotechnology to create two primary platform solutions: the SNAP vaccine platform and Chemophototherapy for targeted oncology. The company is advancing a pipeline targeting infectious diseases, cancer, and chronic conditions like Alzheimer's, supported by significant non-dilutive funding from entities like the NIH and CEPI. As a private, platform-focused biotech, POP BIO partners with global health organizations and seeks collaborators to expand the application of its versatile nanoparticle technology.

View full company profile

Therapeutic Areas

Infectious Disease Oncology Neurology

Other Alzheimer's Disease Drugs

Drug	Company	Phase	Status
NUZ-001	Neurizon Therapeutics	Preclinical	Active
ALZN002	Alzamend Neuro	Preclinical	Research
P021	Phanes Biotech	Preclinical	Active
PB43D	Phanes Biotech	Preclinical	Active
UB-311	Vaxxinity	Phase 2	Active
Lecanemab	BioArctic	Launched	Active (Commercial)
BAN2401	BioArctic	Preclinical	Active
Undisclosed Programs	johnson-and-johnson-innovative-medicine	Pipeline	Active
MK-6240 (florquinitau)	Lantheus Medical Imaging	Regulatory Filing	Filed
NAV-4694 (flutafuranol)	Lantheus Medical Imaging	Phase 3	Active
LNTH-2620/PI-2620	Lantheus Medical Imaging	Phase 3	Recruiting
itMSCs	Stemedica Cell Technologies	Clinical Development	Active